Thomas E. Hutson
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 139
- Prostate Cancer Treatment and Research 20
-
- Cancer Genomics and Diagnostics 40
- Co-authors
- Robert John Motzer (47 shared papers)Stéphane Marie. Oudard (11 shared papers)Robert A. Figlin (36 shared papers)Ronald M. Bukowski (25 shared papers)Sylvie Négrier (10 shared papers)Cezary A. Szczylik (7 shared papers)Bernard J. Escudier (32 shared papers)Marc Dror Michaelson (16 shared papers)
- Journals
- Clinical Genitourinary Cancer (23 papers)Annals of Oncology (20 papers)Journal of Clinical Oncology (20 papers)Cancer (13 papers)The Lancet Oncology (11 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Thomas E. Hutson
205 papers receiving 39.2k citations
Thomas E. Hutson's Hit Papers
Peers
Comparison fields: 5 of 133
- Pulmonary and Respiratory Medicine 24.6k
- Cancer Research 9.0k
- Oncology 10.2k
- Molecular Biology 15.6k
- Pathology and Forensic Medicine 1.6k
Countries citing papers authored by Thomas E. Hutson
This map shows the geographic impact of Thomas E. Hutson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Hutson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Hutson more than expected).
Fields of papers citing papers by Thomas E. Hutson
This network shows the impact of papers produced by Thomas E. Hutson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Hutson. The network helps show where Thomas E. Hutson may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas E. Hutson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 209 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4810 |
| 2 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4078 |
| 3 | Abiraterone and Increased Survival in Metastatic Prostate Cancer Hit paper breakdown → | 2011 | 3637 |
| 4 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2538 |
| 5 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 6 | Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Hit paper breakdown → | 2012 | 1823 |
| 7 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2013 | 1579 |
| 8 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 9 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 10 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 11 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 12 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 983 |
| 13 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 934 |
| 14 | RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors Hit paper breakdown → | 2012 | 889 |
| 15 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Hit paper breakdown → | 2015 | 779 |
| 16 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2016 | 778 |
| 17 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 610 |
| 18 | Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy Hit paper breakdown → | 2011 | 547 |
| 19 | Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 406 |
| 20 | Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial Hit paper breakdown → | 2013 | 360 |
About Thomas E. Hutson
Thomas E. Hutson is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Surgery, having authored 209 papers that have together received 40.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (139 papers), Renal and related cancers (43 papers), Cancer Genomics and Diagnostics (40 papers), Prostate Cancer Treatment and Research (20 papers), Bladder and Urothelial Cancer Treatments (17 papers), Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (24.6k citations), Cancer Research (9.0k citations), Oncology (10.2k citations), Molecular Biology (15.6k citations) and Pathology and Forensic Medicine (1.6k citations). Thomas E. Hutson has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Robert John Motzer, Stéphane Marie. Oudard, Robert A. Figlin, Ronald M. Bukowski, Sylvie Négrier, Cezary A. Szczylik, Bernard J. Escudier, Marc Dror Michaelson, Sindy T. Kim and Piotr Tomczak. Their work appears in journals such as Clinical Genitourinary Cancer, Annals of Oncology, Journal of Clinical Oncology, Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.